Cost-effectiveness analysis of pneumococcal vaccination of adults and elderly persons in Belgium

PharmacoEconomics

Volumn 17, Issue 6, 2000, Pages 591-601

  De Graeve, Diana ^a   Lombaert, Geert ^a   Goossens, Herman ^b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULT; AGED; ARTICLE; BELGIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ELDERLY CARE; HOSPITAL COST; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENINGITIS; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS INFECTION;

EID: 0034101109     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200017060-00005     Document Type: Article

References (29)

1. 1. Peetermans W, Bachez P, Peleman R, et al. Belgian consensus on pneumococcal vaccine. Acta Clin Belg 1996; 51 (5): 350-6
2. 2. Centers for Disease Control. Recommendations of the Immunization Practices Advisory Committee: pneumococcal polysaccharide vaccine. MMWR Morb Mortal Wkly Rep 1989; 38: 64-8, 73-6
3. 3. MacFarlane J. An overview of community-acquired pneumonia with lessons learned from the British Thoracic Society study. Semin Respir Infect 1994; 9 (3): 153-65
4. 4. Musher DM. Infections caused by Streptococcus pneumonia: clinical spectrum, pathogenesis, immunity and treatment. Clin Infect Dis 1992; 14: 801-9
5. 5. Fedson DS. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost-effectiveness. Semin Respir Infect 1993; 8 (4): 285-93
6. 6. Spika JS, Fedson DS, Facklam RR. Pneumococcal vaccination: controversies and opportunities. Infect Dis Clin North Am 1990; 4 (1): 11-27
7. 7. Baltussen RMPM, Ament AJHA, Leidl RM. Economic aspects of vaccinating the elderly against pneumococcal pneumonia. Maastricht: University of Limburg, Department of Health Economics, 1996
8. 8. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333: 1618-24
9. 9. Shann F. Modern vaccines: pneumococcus and influenza. Lancet 1990; 335: 898-901
10. 10. Breiman RF, Spika JS, Navarro VJ, et al. Pneumococcal bacteremia in Charlestone County, South Carolina: a decade later. Arch Intern Med 1990; 150: 1401-5
11. 11. Finch RG. Pneumococcus. In: Greenwood D, Slack RC, Peutherer JF, et al., editors. Medical microbiology. Edinburgh: Churchill Livingstone, 1992: 223-9
12. 12. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. Arch Intern Med 1994; 154: 2666-77
13. 13. Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993; 270 (15): 1826-31
14. 14. Forrester HL, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high-risk population. Am J Med 1987; 83: 425-30
15. 15. Sims RV, Steinmann WC, McConville JH, et al. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988; 108: 653-7
16. 16. Farr BM, Johnston BL, Cobb DK, et al. Preventing pneumococcal bacteremia in patients at risk: results of a matched case-control study. Arch Intern Med 1995; 155: 2336-40
17. 17. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325 (21): 1453-60
18. 18. Sisk JE, Riegelman RK. Cost effectiveness of vaccination against pneumococcal pneumonia: an update. Ann Intern Med 1986; 104: 79-86
19. 19. Gable CB, Holzer SS, Engelhart L, et al. Pneumococcal vaccine: efficacy and associated cost savings. JAMA 1990; 264 (22): 2910-5
20. 20. Patrick KM, Woolley FR. A cost-benefit analysis of immunization for pneumococcal pneumonia. JAMA 1981; 245 (5): 473-7
21. 21. Willems JS, Sanders CR, Riddiough MA, et al. Cost effectiveness of vaccination against pneumococcal pneumonia. N Engl J Med 1980; 303 (10): 553-9
22. 22. Mäkelä PH, Jokinen C, Pyhälä R, et al. Use of vaccines for respiratory infections: strategies for influenza and pneumococcal vaccines. Scand J Infect Dis 1990; 70 Suppl.: 141-8
23. 23. Sanford J, Gilbert D, Gerberding J, et al. The Sanford guide to antimicrobial therapy: Belgian edition. Dallas (TX): Antimicrobial Therapy Inc., 1994
24. 24. Peetermans W, Lacante P. Pneumococcal vaccination by general practitioners: an evaluation of current practice. Vaccine 2000; 18: 612-7
25. 25. Tengs T, Adams M, Pliskin J, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 7995; 15 (3): 369-90
26. 26. Gable C, Botteman M, Savage G, et al. The cost effectiveness of pneumococcal vaccination strategies. Pharmacoeconomics 1997; 12: 161-74
27. 27. Sisk J, Moskowitz A, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1998; 278: 1333-9
28. 28. Ducoffre G, Walckiers D, Glupczynski Y, et al. Evolution des infections à pneumocoques en Belgique de 1986 à 1991. Acta Clin Belg 1993; 48 (3): 148-55
29. 29. Verhaegen J, Glupczynski Y, Verbist L, et al. Capsular types and antibiotic susceptibility of pneumococci isolated from patients in Belgium with serious infections, 1980-1993. Clin Infect Dis 1995; 20: 1339-45